POR006

POR006 is a novel therapeutic target specifically associated with squamous cell carcinoma (SQCC), including lung and head and neck SQCC. It was identified by the biotech company Portrai using their PortraiTARGET spatial transcriptomics platform, which prioritizes targets based on high tumor specificity and spatial homogeneity within the tumor microenvironment. POR006 is characterized by high expression in SQCC tissues and minimal expression across a wide range of normal tissues, making it a promising candidate for precision oncology. Current therapeutic strategies targeting POR006 include the development of high-affinity human antibodies, antibody-drug conjugates (ADCs), and radiopharmaceuticals. These agents are designed to selectively bind to POR006-positive cells to deliver cytotoxic payloads or radioisotopes, with preliminary studies demonstrating sub-nanomolar binding affinities and effective internalization.

Other names

Portrai 006POR-006

Antibody-drug conjugate (ADC) mediated cytotoxicity and targeted radionuclide therapy through selective binding to POR006-expressing cells.